<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="abs0005">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="lis0005">
   <list-item id="lsti0005">
    <label>•</label>
    <p id="par0005">Viral infections such as SARS-CoV-2 (COVID-19), influenza, RSV, and many others are usually associated with increased oxidative stress leading to oxidative cellular and tissue damage resulting in multi-organ failure.</p>
   </list-item>
   <list-item id="lsti0010">
    <label>•</label>
    <p id="par0010">Vitamin C has demonstrated favorable therapeutic properties safety profile throughout a wide range of clinical application.</p>
   </list-item>
   <list-item id="lsti0015">
    <label>•</label>
    <p id="par0015">Administration of high dose of vitamin C as therapeutic agent can favorably impact patient with viral pneumonia and ARDS in severe SAR-CoV-2 infected patients by decreasing inflammation, pathogens infectiveness and virulence, optimizing immune defense, reducing tissues and organs injuries and improving the overall outcome of the disease.</p>
   </list-item>
   <list-item id="lsti0020">
    <label>•</label>
    <p id="par0020">Other nutraceutical antioxidants that widely available as OTC drugs or food supplements can be used to improve redox balance and reduce the tissue damages in patients with viral pneumonia and ARDS</p>
   </list-item>
   <list-item id="lsti0025">
    <label>•</label>
    <p id="par0025">Further clinical trials are needed to validate the effectiveness and develop an optimal therapeutic protocol for high dose of vitamin C treatment for pneumonia and ARDS in patients with viral infection.</p>
   </list-item>
  </list>
 </p>
</abstract>
